DURECT Announces Launch of First FDA Approved SABER Injectable Peptide Product

DURECT Corporation DRRX today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate Equine, an injectable animal health drug utilizing DURECT's SABER™ technology to deliver the peptide deslorelin. DURECT will receive a royalty on net sales of SucroMate and will supply one of the key excipients in SucroMate. Although this product represents a modest revenue opportunity for DURECT by itself, the SABER technology is the basis for our POSIDUR program currently in a pivotal Phase III clinical trial as well as multiple on-going feasibility projects seeking to deliver proteins and peptides for periods of up to one month from a single injection.